Robert W. Baird analyst Michael Ulz maintained a Buy rating on Constellation Pharmaceuticals (CNST) yesterday. The company’s shares closed last Thursday at $27.05.
According to TipRanks.com, Ulz is a 4-star analyst with an average return of 9.2% and a 51.8% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Constellation Pharmaceuticals is a Strong Buy with an average price target of $47.25, implying a 69.1% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $50.90 and a one-year low of $17.00. Currently, Constellation Pharmaceuticals has an average volume of 608.3K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CNST in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.
